Literature DB >> 9534190

Molecular genetics of hereditary ovarian cancer.

J Boyd1.   

Abstract

Approximately 10% of all epithelial ovarian carcinoma cases are associated with inheritance of an autosomal-dominant genetic mutation conferring a predisposition to cancer with variable penetrance. Two such manifestations of hereditary ovarian cancer are currently recognized: the breast and ovarian cancer syndrome and the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome. The breast and ovarian cancer syndrome is linked to the BRCA1 gene on chromosome 17q and, to a lesser extent, to the BRCA2 gene on chromosome 13q. The HNPCC syndrome is caused by any one of three known genes, hMSH2, hMLH1, and hPMS2, that encode proteins involved in the same pathway of DNA mismatch repair. Genetic screening for germ-line transmission of a defective allele of these genes is now possible for high-risk individuals. Despite the rapid pace of research advances in this area, however, considerable uncertainties remain regarding factors that affect the penetrance and tissue-specific expressivity of these mutations. Current research challenges include elucidating these modifying factors, gaining a better understanding of the biological function of BRCA1 and BRCA2 products, and determining the appropriate clinical intervention for genetically predisposed patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9534190

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  12 in total

1.  Polymorphisms in the MUC16 gene: potential implication in epithelial ovarian cancer.

Authors:  Houda Bouanene; Hassen Hadj Kacem; Leila Ben Fatma; Halima Ben Limem; Slim Ben Ahmed; Salwa Yakoub; Abdelhédi Miled
Journal:  Pathol Oncol Res       Date:  2010-11-03       Impact factor: 3.201

2.  Expression of EMSY gene in sporadic ovarian cancer.

Authors:  Julide Altinisik; Ates Karateke; Hakan Coksuer; Turgut Ulutin; Nur Buyru
Journal:  Mol Biol Rep       Date:  2010-03-28       Impact factor: 2.316

3.  [Radiological diagnostics of ovarian cancer].

Authors:  M Meissnitzer; R Forstner
Journal:  Radiologe       Date:  2011-07       Impact factor: 0.635

4.  Should mammographic screening be done in primary ovarian cancer?: A case control study in Turkish women.

Authors:  M Ozguroglu; B Avci; H Turna; G Esen; B Arun; V Celik; S Serdengeçti
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

Review 5.  Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.

Authors:  Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin
Journal:  Mol Oncol       Date:  2009-02-21       Impact factor: 6.603

6.  Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.

Authors:  Murray Joseph Casey; Chhanda Bewtra; Henry T Lynch; Carrie Snyder; Mark Stacy; Patrice Watson
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

7.  TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.

Authors:  Pedro Kringen; Yun Wang; Vanessa Dumeaux; Jahn M Nesland; Gunnar Kristensen; Anne-Lise Borresen-Dale; Anne Dorum
Journal:  BMC Cancer       Date:  2005-10-17       Impact factor: 4.430

Review 8.  Clinical epidemiology of epithelial ovarian cancer in the UK.

Authors:  Konstantinos Doufekas; Adeola Olaitan
Journal:  Int J Womens Health       Date:  2014-05-23

Review 9.  Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma.

Authors:  Mohammad Ezzati; Amer Abdullah; Ahmad Shariftabrizi; June Hou; Michael Kopf; Jennifer K Stedman; Robert Samuelson; Shohreh Shahabi
Journal:  Int Sch Res Notices       Date:  2014-10-29

Review 10.  Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer.

Authors:  Dmitri Pchejetski; Albandri Alfraidi; Keith Sacco; Heba Alshaker; Aun Muhammad; Leonardo Monzon
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-11       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.